These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14528918)

  • 1. Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study.
    Cheng H; Xu J; McKeel DW; Han X
    Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):809-18. PubMed ID: 14528918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis.
    Han X; M Holtzman D; McKeel DW; Kelley J; Morris JC
    J Neurochem; 2002 Aug; 82(4):809-18. PubMed ID: 12358786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting bioactive amyloid beta peptide species in Alzheimer's disease.
    Liu Y; Dargusch R; Banh C; Miller CA; Schubert D
    J Neurochem; 2004 Nov; 91(3):648-56. PubMed ID: 15485495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor.
    Barrachina M; Dalfó E; Puig B; Vidal N; Freixes M; Castaño E; Ferrer I
    Neurochem Int; 2005 Feb; 46(3):253-60. PubMed ID: 15670642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A turn of the sulfatide in Alzheimer's disease.
    Irizarry MC
    Ann Neurol; 2003 Jul; 54(1):7-8. PubMed ID: 12838515
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's disease-like neuroinflammation and cognitive impairment.
    Qiu S; Palavicini JP; Wang J; Gonzalez NS; He S; Dustin E; Zou C; Ding L; Bhattacharjee A; Van Skike CE; Galvan V; Dupree JL; Han X
    Mol Neurodegener; 2021 Sep; 16(1):64. PubMed ID: 34526055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease.
    Ferrer I; Freixas M; Blanco R; Carmona M; Puig B
    Neuropathol Appl Neurobiol; 2004 Aug; 30(4):329-37. PubMed ID: 15305978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry.
    Grimm MO; Grösgen S; Riemenschneider M; Tanila H; Grimm HS; Hartmann T
    J Chromatogr A; 2011 Oct; 1218(42):7713-22. PubMed ID: 21872257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
    Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
    Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies.
    Deramecourt V; Bombois S; Maurage CA; Ghestem A; Drobecq H; Vanmechelen E; Lebert F; Pasquier F; Delacourte A
    J Neuropathol Exp Neurol; 2006 Mar; 65(3):278-88. PubMed ID: 16651889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
    Roy S; Rauk A
    Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease.
    Bruno MA; Leon WC; Fragoso G; Mushynski WE; Almazan G; Cuello AC
    J Neuropathol Exp Neurol; 2009 Aug; 68(8):857-69. PubMed ID: 19606067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study.
    Hermansson M; Käkelä R; Berghäll M; Lehesjoki AE; Somerharju P; Lahtinen U
    J Neurochem; 2005 Nov; 95(3):609-17. PubMed ID: 16086686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
    Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
    Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.